Clinical Trial

Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with vitiligo.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-12.
Status change: Active, Not Recruiting → Completed 2026-06-03
Trial Details
NCT Number NCT07181187
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions Vitiligo
Enrollment 156 participants
Start Date 2024-03-26
Primary Completion 2025-09-24 (estimated)
Study Completion 2026-05-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-04